Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of new quinolones against Helicobacter pylori.

Literature DB >> 9420062

In vitro activities of new quinolones against Helicobacter pylori.

M Carbone¹, M T Fera, V Cecchetti, O Tabarrini, E Losi, V Cusumano, G Teti.

Abstract

Compounds belonging to a new class of quinolones in which the fundamental C-6 fluorine atom was replaced were evaluated for in vitro antibacterial activity against 32 Helicobacter pylori strains. Since these substitutions resulted in higher inhibitory activities, these new desfluoroquinolones may be useful in eradicating H. pylori infections.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1997 PMID： 9420062 PMCID： PMC164212

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

25 in total

1. Metronidazole resistance in Helicobacter pylori.

Authors: Y Glupczynski; A Burette; E De Koster; J F Nyst; M Deltenre; S Cadranel; L Bourdeaux; D De Vos
Journal: Lancet Date: 1990-04-21 Impact factor: 79.321

2. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment.

Authors: E A Rauws; W Langenberg; H J Houthoff; H C Zanen; G N Tytgat
Journal: Gastroenterology Date: 1988-01 Impact factor: 22.682

Review 2. The future of the quinolones.

Authors: V T Andriole
Journal: Drugs Date: 1999 Impact factor: 9.546

2 in total

In vitro activities of new quinolones against Helicobacter pylori.

1. Metronidazole resistance in Helicobacter pylori.

2. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment.

3. Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach.

4. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.

5. Treatment failure of ofloxacin in Campylobacter pylori infection.

6. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis.

7. The in vitro and in vivo activity of ciprofloxacin.

8. In vitro susceptibilities of Campylobacter-like organisms to twenty antimicrobial agents.

9. Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents.

10. Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa.

1. In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657.

Review 2. The future of the quinolones.